VAXCYTE, INC. Operating Lease, Expense
VAXCYTE, INC. (PCVX) reported Operating Lease, Expense of $5.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-05
- VAXCYTE, INC. operating lease, expense for the quarter ending 2026-06-30 was $5.40M, a 38.46% increase year-over-year.
- VAXCYTE, INC. operating lease, expense for the quarter ending 2026-03-31 was $5.50M, a 52.78% increase year-over-year.
- VAXCYTE, INC. operating lease, expense for the quarter ending 2025-12-31 was $4.00M, a 42.86% increase year-over-year.
- VAXCYTE, INC. operating lease, expense for the quarter ending 2025-09-30 was $3.90M, a 18.18% increase year-over-year.
- VAXCYTE, INC. operating lease, expense for fiscal 2025 was $15.40M, a 33.91% increase from fiscal 2024.
- VAXCYTE, INC. operating lease, expense for fiscal 2024 was $11.50M, a 35.29% increase from fiscal 2023.
- VAXCYTE, INC. operating lease, expense for fiscal 2023 was $8.50M, a 7.59% increase from fiscal 2022.
- VAXCYTE, INC. operating lease, expense for fiscal 2022 was $7.90M, a 146.88% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.40M 10-Q · filed 2026-08-05 | $10.90M 10-Q · filed 2026-08-05 | $14.90M derived: sum of 3 quarters · filed 2026-08-05 | $18.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.50M 10-Q · filed 2026-05-06 | $9.50M derived: sum of 2 quarters · filed 2026-05-06 | $13.40M derived: sum of 3 quarters · filed 2026-05-06 | $17.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.90M derived: sum of 2 quarters · filed 2026-02-24 | $11.80M derived: sum of 3 quarters · filed 2026-08-05 | $15.40M 10-K · filed 2026-02-24 |
| 2025-09-30 | $3.90M 10-Q · filed 2025-11-04 | $7.80M derived: sum of 2 quarters · filed 2026-08-05 | $11.40M 10-Q · filed 2025-11-04 | $14.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.90M 10-Q · filed 2026-08-05 | $7.50M 10-Q · filed 2026-08-05 | $10.30M derived: sum of 3 quarters · filed 2026-08-05 | $13.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.60M 10-Q · filed 2026-05-06 | $6.40M derived: sum of 2 quarters · filed 2026-05-06 | $9.70M derived: sum of 3 quarters · filed 2026-05-06 | $12.40M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.10M derived: sum of 2 quarters · filed 2026-02-24 | $8.80M derived: sum of 3 quarters · filed 2026-02-24 | $11.50M 10-K · filed 2026-02-24 |
| 2024-09-30 | $3.30M 10-Q · filed 2025-11-04 | $6.00M derived: sum of 2 quarters · filed 2025-11-04 | $8.70M 10-Q · filed 2025-11-04 | $11.40M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.70M 10-Q · filed 2025-08-06 | $5.40M 10-Q · filed 2025-08-06 | $8.10M derived: sum of 3 quarters · filed 2026-02-24 | $10.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.70M 10-Q · filed 2025-05-07 | $5.40M derived: sum of 2 quarters · filed 2026-02-24 | $7.30M derived: sum of 3 quarters · filed 2026-02-24 | $9.20M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.60M derived: sum of 2 quarters · filed 2026-02-24 | $6.50M derived: sum of 3 quarters · filed 2026-02-24 | $8.50M 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.90M 10-Q · filed 2024-11-05 | $3.80M derived: sum of 2 quarters · filed 2024-11-05 | $5.80M 10-Q · filed 2024-11-05 | $7.60M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.90M 10-Q · filed 2024-08-06 | $3.90M 10-Q · filed 2024-08-06 | $5.70M derived: sum of 3 quarters · filed 2025-02-25 | $7.60M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.90M 10-Q · filed 2024-05-08 | $3.80M derived: sum of 2 quarters · filed 2025-02-25 | $5.70M derived: sum of 3 quarters · filed 2025-02-25 | $7.70M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $3.80M derived: sum of 2 quarters · filed 2025-02-25 | $5.80M derived: sum of 3 quarters · filed 2025-02-25 | $7.90M 10-K · filed 2025-02-25 |
| 2022-09-30 | $1.90M 10-Q · filed 2023-11-06 | $3.90M derived: sum of 2 quarters · filed 2023-11-06 | $6.00M 10-Q · filed 2023-11-06 | $7.40M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $2.00M 10-Q · filed 2023-08-08 | $4.10M 10-Q · filed 2023-08-08 | $5.50M derived: sum of 3 quarters · filed 2024-02-27 | $6.50M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $2.20M 10-Q · filed 2023-05-08 | $3.50M derived: sum of 2 quarters · filed 2024-02-27 | $4.50M derived: sum of 3 quarters · filed 2024-02-27 | $5.10M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.30M derived: sum of 2 quarters · filed 2024-02-27 | $2.90M derived: sum of 3 quarters · filed 2024-02-27 | $3.20M 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.00M 10-Q · filed 2022-11-07 | $1.60M derived: sum of 2 quarters · filed 2022-11-07 | $1.90M 10-Q · filed 2022-11-07 | $2.20M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $600.00K 10-Q · filed 2022-08-08 | $900.00K 10-Q · filed 2022-08-08 | $1.20M derived: sum of 3 quarters · filed 2023-02-27 | $1.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $400.00K 10-Q · filed 2022-05-09 | $600.00K derived: sum of 2 quarters · filed 2023-02-27 | $800.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $400.00K derived: sum of 2 quarters · filed 2023-02-27 | $600.00K derived: sum of 3 quarters · filed 2023-02-27 | $700.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-10 | $400.00K derived: sum of 2 quarters · filed 2021-11-10 | $500.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $200.00K 10-Q · filed 2021-08-11 | $300.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $600.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |